Discovery of BBO-11818 as a selective inhibitor for KRAS mutants, suggesting potential for monotherapy or combination treatments.
We discovered BBO-11818, a potent and selective noncovalent KRAS inhibitor with activity against multiple KRAS mutants in both the active (ON) and inactive (OFF) states. BBO-11818 addresses the need for KRAS inhibitors targeting clinically relevant mutants such as KRASG12D and KRASG12V, either as monotherapy or in combination.
No takes yet. Share an insight, caveat, or question.
Stahlhut et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: